Alexion NEPH-202 Ravulizumab trial

Brief description of study

The purpose of the study is to evaluate the safety and efficacy of the study treatment in participants with Lupus Nephritis (LN).This study involves an investigational treatment called ALXN1210 which is also known as ravulizumab and is referred to as “study treatment” in this form. “Investigational” means the drug is not approved by the US Food and Drug Administration (FDA) for this purpose. It is being developed for the treatment of LN. The study treatment binds to the C5 protein of the complement system. The complement system is part of the body’s immune system (system that fights against infections). Dysregulation of the complement system is a contributing factor for the cause of LN. The study treatment works by reducing complement activity

Clinical Study Identifier: s20-01762 Identifier: NCT04564339
Principal Investigator: Howard Belmont.
Other Investigator: Janine M. Sullivan.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.